Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis

Cancer Letters

Volumn 359, Issue 1, 2015, Pages 107-116

  Joseph, Justin V ^a   Conroy, Siobhan ^a   Pavlov, Kirill ^a   Sontakke, Pallavi ^a   Tomar, Tushar ^a   Eggens Meijer, Ellie ^a   Balasubramaniyan, Veerakumar ^a   Wagemakers, Michiel ^a   den Dunnen, Wilfred F A ^a   Kruyt, Frank A E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

GBM; Hypoxia; Invasion; Mesenchymal phenotype

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR ZEB1; ADIPOCYTOKINE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CHI3L1 PROTEIN, HUMAN; DIGOXIN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; LECTIN; SLC2A1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYPOXIA; MESENCHYME CELL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR INVASION; BRAIN TUMOR; CELL HYPOXIA; CELL MOTION; CELL SHAPE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; METABOLISM; NECROSIS; PATHOLOGY; PHENOTYPE; RNA INTERFERENCE; TUMOR CELL LINE;

ADIPOKINES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL SHAPE; DIGOXIN; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOBLASTOMA; GLUCOSE TRANSPORTER TYPE 1; HOMEODOMAIN PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LECTINS; NECROSIS; NEOPLASM INVASIVENESS; PHENOTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84922222306     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.010     Document Type: Article

References (46)

1. Huse J.T., Holland E.C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 2010, 10(5):319-331.
2. Wen P.Y., Kesari S. Malignant gliomas in adults. N. Engl. J. Med 2008, 359(5):492-507.
3. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9(3):157-173.
4. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110.
5. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59(8):1190-1199.
6. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463(7279):318-325.
7. Cooper L.A., Gutman D.A., Chisolm C., Appin C., Kong J., Rong Y., et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am. J. Pathol 2012, 180(5):2108-2119.
8. Evans S.M., Judy K.D., Dunphy I., Jenkins W.T., Hwang W.T., Nelson P.T., et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res 2004, 10(24):8177-8184.
9. Brat D.J., Castellano-Sanchez A.A., Hunter S.B., Pecot M., Cohen C., Hammond E.H., et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004, 64(3):920-927.
10. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev 1994, 13(2):139-168.
11. Liang B.C. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J. Neurooncol 1996, 29(2):149-155.
12. Semenza G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004, 5(5):405-406.
13. Chi J.T., Wang Z., Nuyten D.S., Rodriguez E.H., Schaner M.E., Salim A., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3(3):e47.
14. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
15. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E., McLendon R.E., Desjardins A., et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol 2008, 26(2):271-278.
16. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2(1):38-47.
17. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129(3):465-472.
18. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19(16):4298-4309.
19. Yu F., White S.B., Zhao Q., Lee F.S. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer Res 2001, 61(10):4136-4142.
20. Holmquist-Mengelbier L., Fredlund E., Löfstedt T., Noguera R., Navarro S., Nilsson H., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006, 10(5):413-423.
21. Liu L., Salnikov A.V., Bauer N., Aleksandrowicz E., Labsch S., Nwaeburu C., et al. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int. J. Cancer 2014, 134(10):2489-2503.
22. Liu Y., Liu Y., Yan X., Xu Y., Luo F., Ye J., et al. HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT. Tumour Biol 2014, 35(8):8103-8114.
23. Du J., Sun B., Zhao X., Gu Q., Dong X., Mo J., et al. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol. Oncol 2014, 133(3):575-583.
24. Shaikh D., Zhou Q., Chen T., Ibe J.C., Raj J.U., Zhou G. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial-mesenchymal transition, migration, and invasion in lung cancer cells. Cell. Signal 2012, 24(12):2396-2406.
25. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14(6):818-829.
26. Giese A., Bjerkvig R., Berens M.E., Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol 2003, 21(8):1624-1636.
27. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J. Neurooncol 2004, 70(2):217-228.
28. Joseph J.V., Conroy S., Tomar T., Eggens-Meijer E., Bhat K., Copray S., et al. TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis 2014, 5:e1443.
29. Wierenga A.T., Vellenga E., Schuringa J.J. Down-regulation of GATA1 uncouples STAT5-induced erythroid differentiation from stem/progenitor cell proliferation. Blood 2010, 115(22):4367-4376.
30. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol 2011, 13:317-323.
31. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(50):19579-19586.
32. Rong Y., Durden D.L., Van Meir E.G., Brat D.J. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol 2006, 65(6):529-539.
33. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem. Pharmacol 2006, 72(1):19-31.
34. Hsieh C.H., Shyu W.C., Chiang C.Y., Kuo J.W., Shen W.C., Liu R.S. NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme. PLoS ONE 2011, 6(9):e23945.
35. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov 2011, 10(6):417-427.
36. Jensen R.L. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neurooncol 2009, 92(3):317-335.
37. Mathew L.K., Skuli N., Mucaj V., Lee S.S., Zinn P.O., Sathyan P., et al. miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 2014, 111(1):291-296.
38. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15(6):501-513.
39. Seidel S., Garvalov B.K., Wirta V., von Stechow L., Schänzer A., Meletis K., et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133(Pt 4):983-995.
40. Liu T.Z., Wang X., Bai Y.F., Liao H.Z., Qiu S.C., Yang Y.Q., et al. The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor. Int. J. Biochem. Cell Biol 2014, 49:8-16.
41. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
42. Chaffer C.L., Marjanovic N.D., Lee T., Bell G., Kleer C.G., Reinhardt F., et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154(1):61-74.
43. Siebzehnrubl F.A., Silver D.J., Tugertimur B., Deleyrolle L.P., Siebzehnrubl D., Sarkisian M.R., et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol. Med 2013, 5(8):1196-1212.
44. Bhat K.P., Balasubramaniyan V., Vaillant B., Ezhilarasan R., Hummelink K., Hollingsworth F., et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24(3):331-346.
45. Kahlert U.D., Nikkhah G., Maciaczyk J. Epithelial-to-mesenchymal (-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett 2013, 331(2):131-138.
46. Bhat K.P., Salazar K.L., Balasubramaniyan V., Wani K., Heathcock L., Hollingsworth F., et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011, 25(24):2594-2609.